A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) ...
Keep Reading →
August 10 - Hedge Funds, News
The year 2026 has turned into a pivotal year for the biotech capital markets.
Keep Reading →
July 29 - News
June’s biggest American stock winners came during a market where investors were highly rewarding companies tied to earnings growth, AI infrastructure, cyclicals, and sector-...
Keep Reading →
July 7 - Hedge Funds, News
In this article, we will look at the stocks Jim Cramer commented on as he advised investors on how to take advantage of Wednesday’s market rotation.
Keep Reading →
July 3 - Hedge Funds, News
Moderna extended its winning streak to a fifth consecutive day on Wednesday, climbing 11.55 percent to end at $61.80 apiece, as investors loaded their portfolios ahead of its ...
Keep Reading →
June 17 - News
Ten stocks stood firmer on Wednesday, defying a lackluster performance on Wall Street, thanks to a combination of macroeconomic and corporate developments that bolstered buying...
Keep Reading →
June 17 - News
Moderna extended its winning streak to a fourth consecutive day on Tuesday, surging 6.27 percent to close at $55.40 apiece, as investors digested the looming launch of three new...
Keep Reading →
June 16 - News
Meanwhile, only the Dow Jones finished in the green among Wall Street’s three major indices, up 0.64 percent.
Keep Reading →
June 16 - News
Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to finish at $49.06 apiece, as investors positioned portfolios ahead of its participation in a conference...
Keep Reading →
June 3 - News
Ten stocks stood firm despite a bloodbath in the broader market on Wednesday, as investors digested positive industry developments, including strong earnings and optimistic outlooks...
Keep Reading →
June 3 - Market Movers, News
TheFly reported earlier this month, on May 4, that UBS increased its price objective on MRNA to $45 from $36 while continuing to hold a Neutral stance on the stock.
Keep Reading →
June 2 - News
Despite growing geopolitical tensions related to the Iran war, Callanish Capital CEO Haig Bathgate shared an optimistic stance on global markets during an appearance on CNCB on...
Keep Reading →
May 31 - Hedge Funds, News
On April 22, Andrew Slimmon, Morgan Stanley Investment Management Senior Portfolio Manager, joined CNBC's 'Squawk Box' to discuss the latest market trends.
Keep Reading →
April 28 - Hedge Funds, News
In this article, we will look at Jim Cramer’s review of the S&P 500’s top performers and the Nasdaq 100’s biggest laggards for the first quarter.
Keep Reading →
April 3 - Hedge Funds, News
Moderna snapped a two-day losing streak on Wednesday, jumping 15.99 percent to finish at $57.80 apiece after resolving a four-year legal dispute with two biopharmaceutical companies...
Keep Reading →
March 4 - News
On January 28, Barclays assumed coverage of Moderna, Inc.
Keep Reading →
February 11 - News
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals...
Keep Reading →
February 10 - Hedge Funds, News
Moderna, Inc. (NASDAQ:MRNA) is one of the best healthcare stocks under $50 to invest in. Morgan Stanley reiterated a Hold rating on Moderna, Inc.
Keep Reading →
February 10 - News
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage...
Keep Reading →
February 9 - Hedge Funds, News
I don't usually start the game plan on Wednesday, but that's when we get the employment report this time, and it's kind of screwed up because of the government shutdown.
Keep Reading →
February 9 - Hedge Funds, News
The first month of 2026 is officially in the books. So before we move on to another very busy week of earnings, I want to go over the state of the market.
Keep Reading →
February 4 - Hedge Funds, News
I never thought I'd say this, but the United States increasingly feels like a command economy where you better accept the president's terms without complaints or suffer the consequences...
Keep Reading →
January 29 - News
Moderna surged to a new 52-week high of $50 on Wednesday, a 16 percent jump, as investors took heart from the strong results of its clinical study for Intismeran Autogene in Combination...
Keep Reading →
January 22 - News
Moderna Inc. (NASDAQ:MRNA)’s shares are up by 16% over the past year and by 31% year-to-date.
Keep Reading →
January 16 - News
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the impact of the Justice Department serving the Federal Reserve with grand jury subpoenas and threatening...
Keep Reading →
January 15 - News
At the 44th Annual JP Morgan Healthcare Conference on Monday, Moderna Inc.
Keep Reading →
January 14 - News
Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now.
Keep Reading →
December 11 - News
On December 8, Bob Doll, Crossmark Global Investments CEO and CIO, joined CNBC’s ‘Squawk on the Street’ to discuss the latest market trends and his expectations for the ...
Keep Reading →
December 10 - Hedge Funds, News
Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts.
Keep Reading →
October 17 - News
On October 9, Keith Buchanan, Senior Portfolio Manager at GLOBALT Investments, appeared on CNBC and stated that the markets show mixed signals of risk and optimism.
Keep Reading →
October 16 - Hedge Funds, News
Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.
Keep Reading →
October 2 - News
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
Keep Reading →
September 30 - Hedge Funds, News
Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, specializes in mRNA therapeutics and vaccines, including its flagship COVID-19 vaccine.
Keep Reading →
September 21 - News
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC's "Squawk Box" on July 25 to discuss a variety of topics, including the status of the biotech...
Keep Reading →
September 18 - Hedge Funds, News
Moderna, Inc. (NASDAQ:MRNA) is the ill-fated vaccine company that has continued to struggle after the COVID-19 pandemic’s end.
Keep Reading →
September 7 - News
In his recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed how the threat of fines, levies, or tariffs against American companies by European nations was being...
Keep Reading →
September 5 - News
Moderna, Inc. (NASDAQ:MRNA) ranks among the best mid-cap stocks with huge upside potential. Moderna, Inc.
Keep Reading →
September 2 - News
The Federal Reserve's favored inflation indicator showed a modest increase in July inflation, suggesting that President Donald Trump's tariffs are having an impact on the American...
Keep Reading →
August 31 - Hedge Funds, News
Moderna, Inc. (NASDAQ:MRNA) stands fifth among the best cancer stocks.
Keep Reading →
August 28 - News
Moderna, Inc. (NASDAQ:MRNA) is among the 13 Best S&P 500 Stocks to Buy According to Wall Street Analysts, based on upside potential.
Keep Reading →
August 24 - News
Cancer remains the second leading cause of death globally, after heart disease.
Keep Reading →
August 24 - Lists, News
The S&P 500 index dipped 0.24% to close at 6,395.78 on Wednesday, marking its fourth successive day of losses, sparked by an ongoing tech sell-off.
Keep Reading →
August 23 - Hedge Funds, News
We recently published 10 Stocks Jim Cramer Mentioned As He Talked About “Love Lost” Between Microsoft & OpenAI. Moderna, Inc.
Keep Reading →
August 9 - News
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the relationship between Microsoft and OpenAI.
Keep Reading →
August 8 - News
Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed against Health Secretary Robert F. Kennedy Jr.
Keep Reading →
July 9 - News
Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now.
Keep Reading →
June 24 - News
On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC's 'Closing Bell Overtime' to talk about how the market sell-off is an opportunity to step in.
Keep Reading →
June 23 - Hedge Funds, News
On May 31, Bloomberg reported that the FDA recently granted Moderna Inc. (NASDAQ:MRNA) a narrower approval for its next-generation COVID-19 vaccine.
Keep Reading →
June 2 - News
We recently published a list of Jim Cramer Talked About These 13 Stocks. In this article, we are going to take a look at where Moderna, Inc.
Keep Reading →
May 26 - News
Hedge Fund Resource Center 
